Thermo Fisher wraps up Phadia buy

Thermo Fisher Scientific ($TMO) has completed its previously announced acquisition of Uppsala, Sweden-based Phadia, which has approximately 1,500 employees and had 2010 revenue of roughly $525 million. Phadia manufactures and markets complete blood test systems to support the diagnosis and monitoring of allergy, asthma and autoimmune diseases, according to the company's website.

"We are pleased to complete the acquisition of Phadia, which significantly enhances our presence in high-growth specialty diagnostics markets by adding leading allergy and autoimmunity diagnostic tests," said Marc Casper, president and CEO of Thermo Fisher. "Phadia provides us with growth opportunities in an under-penetrated U.S. market and allows us to leverage our strong presence in emerging geographic markets. We are delighted to welcome Phadia's employees to our team and look forward to working together to expand our depth of capabilities for our customers who are focused on improving healthcare through better diagnostics."

Just this week, Phadia announced it and Denmark's Biomonitor are collaborating in the field of immunogenicity testing and monitoring of patients treated with biopharmaceutical drugs.

- check out the Thermo Fisher release
- see the Phadia statement on the collaboration

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.